Focused Pharmacogenomics Panel
Test in Focus
Mayo Clinic Laboratories’ updated focused pharmacogenomics panel uses real-time, PCR testing for targeted genotyping of 10 genes with known associations to medications used to treat a variety of disorders across a spectrum of specialities. In this “A Test in Focus” episode of the "Answers From the Lab" podcast, Ann Moyer, M.D., Ph.D., explains how this innovative assay helps guide providers on choosing the best treatment option for their patients.
“The goal of this panel would be that it should be useful for patients that are either on many different medications or patients where the differential diagnosis is still rather broad, where it's difficult to decide which medication to put the patient on,” Dr. Moyer says “Because these drugs metabolize so many different medications, hopefully this is a panel that, once the patient has it ordered, it can be reused again and again, throughout their care, no matter what specialty they're seeing.”
By including both genotype and phenotype evaluation of those genes with a high level of evidence for metabolic associations to medications, the test enables detailed insights on patients’ genetic dispositions, Dr. Moyer says. “We tried to be really careful and cognizant about making sure that we include all of the alleles that are relevant for various patient populations throughout the world. And I think that makes our tests something that should be useful for years to come.”
Listen to learn more about how our focused pharmacogenomics panel can help guide treatment selection and improve treatment outcomes for patients.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
- Preemptive or reactive genotyping of patients for pharmacogenomic purposes
- Providing an assessment for genes with strong drug-gene associations
Submit only 1 of the following specimens:
- Specimen Type: Whole blood
- Container/Tube: Lavender top (EDTA)
- Specimen Volume: 3 mL
- Collection Instructions:
- Invert several times to mix blood.
- Send specimen in original tube. Do not aliquot.
- Specimen Stability Information: Ambient (preferred) 9 days/Refrigerated 30 days
- Specimen Type: Saliva
- Patient Preparation: Patient should not eat, drink smoke, or chew gum 30 minutes prior to collection.
- Supplies: Saliva Swab Collection Kit (T786)
- Specimen Volume: 1 Swab
- Collection Instructions: Collect and send specimen per kit instructions.
- Additional Information: Due to lower concentration of DNA yielded from saliva, testing cannot proceed to reflex testing for 2D6 sequencing and will stop after initial testing is complete.
- Specimen Stability Information: Ambient 30 days
- Specimen Type: Extracted DNA
- Container/Tube: 2 mL screw top tube
- Specimen Volume: 100 mcL (microliters)
- Collection Instructions:
- The preferred volume is 100 mcL at a concentration of 50 ng/mcL.
- Include concentration and volume on tube.
- Specimen Stability Information: Frozen (preferred)/Ambient/Refrigerated
- Analytic time: 3 to 14 days
- Day(s) and time(s) performed: Monday through Friday
The latest from Test in Focus
John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat condition known as DADS neuropathy.
Pua Hopson, D.O., discusses Mayo Clinic Labs’ new disaccharidase activity panel, which measures levels of five digestive enzymes to identify deficiencies that cause carbohydrate maldigestion and can lead to chronic conditions like celiac disease or inflammatory bowel disease. Performed on tissue sample biopsies during upper endoscopy, the activity panel is the gold standard test for detecting disaccharidase deficiencies.
Divyanshu (Div) Dubey, M.B.B.S., explains how Mayo Clinic Labs’ new Kelch-11 antibody test — the first in the world — can confirm diagnosis, guide treatment, and improve outcomes in patients affected by testicular cancer-associated paraneoplastic encephalitis.